HARVARD BIOSCIENCE, INC. (NASDAQ:HBIO) Files An 8-K Financial Statements and ExhibitsItem 9.01(a)(1) and to furnish the pro forma financial information required by Item 9.01(b)(1) of Form 8-K relative to the completion of the acquisition of DSI, as previously reported in the Current Report on Form 8-K filed on February 2, 2018.
| Item 9.01. | Financial Statements and Exhibits. |
| (a) | Financial Statements of Business Acquired. |
The audited consolidated financial statements of DSI for the years ended June 30, 2017 and June 30, 2016, respectively, and the notes related thereto, as well as the interim unaudited consolidated financial statements of DSI for the six months ended December 31, 2017 and December 31, 2016, and the notes related thereto are filed as Exhibit 99.1 to this Amendment No. 1 to Form 8-K and are incorporated herein by reference. The Consent of DSI’s independent auditor, RSM US LLP, is filed as Exhibit 23.1 to this Amendment No. 1 to Form 8-K and is incorporated herein by reference.
| (b) | Pro Forma Financial Information. |
The unaudited pro forma condensed combined balance sheet of the Company as of December 31, 2017 and the unaudited pro forma condensed combined statement of operations of the Company for the year ended December 31, 2017, and the notes related thereto, giving effect to the acquisition of DSI, is attached as Exhibit 99.2 hereto and incorporated herein by reference:
(d)Exhibits.
| ExhibitIndex | Description |
| 23.1 | Consent of Independent Auditor RSM US LLP |
| 99.1 | Audited Consolidated Financial Statements of Data Sciences International, Inc. for the years ended June 30, 2017 and June 30, 2016, and the notes related thereto, and interim Unaudited Consolidated Financial Statements of Data Sciences International, Inc. for the six month period ended December 31, 2017 and the six month period ended December 31, 2016, and the notes related thereto |
| 99.2 | Unaudited Pro Forma Condensed Combined Financial Information of Harvard Bioscience, Inc. for the year ended December 31, 2017, and the notes related thereto |
HARVARD BIOSCIENCE INC ExhibitEX-23.1 2 exh_231.htm EXHIBIT 23.1 Exhibit 23.1 Consent of Independent Auditor We consent to the incorporation by reference in the Registration Statements of Harvard Bioscience,…To view the full exhibit click here
About HARVARD BIOSCIENCE, INC. (NASDAQ:HBIO)
Harvard Bioscience, Inc. is a developer, manufacturer and marketer of a range of scientific instruments, systems and lab consumables used for basic research, drug discovery, clinical and environmental testing. The Company’s products are sold to thousands of researchers in over 100 countries through its global sales organization, Websites, catalogs and through distributors. The Company’s product range is organized into three commercial product families: Cell and Animal Physiology (CAP), Lab Products and Services (LPS), and Molecular Separation and Analysis (MSA). The Company sells these products under brand names, including Harvard Apparatus, KD Scientific, Denville Scientific, AHN, Hoefer, Biochrom, BTX, Warner Instruments, MCS, HEKA, Hugo Sachs Elektronik, Panlab, Coulbourn Instruments, TBSI and CMA Microdialysis. The Company’s products consist of instruments, consumables and systems that are made up of various individual products.